Where I see patients (1)
Selected research
-
Case report: sub-clinical extramedullary B-ALL in the setting of relapse following targeted therapy.
Frontiers in immunology
-
Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology Group.
Cancer discovery
-
Prototypical innate immune mechanism hijacked by leukemia-initiating mutant stem cells for selective advantage and immune evasion in Ptpn11-associated juvenile myelomonocytic leukemia.
Research square
Contact me
Translation, please